[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054287":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":17,"studyPopulation":18,"armGroups":13,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":30,"responsibleParty":182,"collaborators":185,"id":202,"slug":203,"hasResults":204,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":210,"sex":211,"minAge":212,"maxAge":13,"enrollmentInfo":213,"targetDuration":216,"studyType":217,"phases":13,"briefSummary":218,"conditions":219,"keywords":13,"overallStatus":33,"whyStopped":13,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},{"fullName":5,"class":6},"St. Joseph's Healthcare Hamilton","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Rate of participation in the master trial platform","Number of participants who consent to be included in the registry","31st March 2026",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","CROSS_SECTIONAL","The ENABLE platform offers to the Canadian neuroscience community (1) standardized data collection methods with deep clinical and neurobiological phenotyping of individuals across the spectrum of mood disorder symptoms; (2) a recruitment pool for efficient launch of clinical trials; and (3) an open source of clinical and neurobiological data for discovery analyses and\u002For grant applications.\n\nThe assessments have been categorized into a tiered system, where participants must consent to complete tier 1 items in order to be enrolled in the platform. Tier 2 items will be optional measures, the absence of these measures will not compromise the inclusion in the platform. A separate question will be included in the informed consent process asking participants whether they agree to be contacted about future clinical trials associated with the ENABLE platform.\n\nAt tier 1, individuals complete clinical assessments (clinician administered and self-report) and during their tier 2, they provide blood, undergo neuroimaging procedures (MRI and EEG); complete a cognitive task (CNS Vital Signs) and are given an actigraphy device to wear for two weeks.","Individuals who meet criteria for bipolar or depressive disorders as defined by DSM-5.",[20],{"name":21,"affiliation":5,"role":22},"Benicio N Frey","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},"Saba Khoshroo","CONTACT","905-522-1155","36462","skhoshro@stjoes.ca",[31,52,69,86,102,119,136,153,165],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"University of Calgary","RECRUITING","Calgary","Alberta","T2N 4Z6","Canada","CA",{"type":40,"coordinates":41},"Point",[42,43],-114.08529,51.05011,{"lat":43,"lon":42},[46,50],{"name":47,"role":26,"phone":48,"phoneExt":13,"email":49},"Alexandra Du","403-220-6533","mi.du@ucalgary.ca",{"name":51,"role":22,"phone":13,"phoneExt":13,"email":13},"Valerie H Taylor, MD, PhD",{"facility":53,"status":33,"city":54,"state":55,"zip":56,"country":37,"countryCode":38,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"University of British Columbia","Vancouver","British Columbia","V6T 2A1",{"type":40,"coordinates":58},[59,60],-123.11934,49.24966,{"lat":60,"lon":59},[63,67],{"name":64,"role":26,"phone":65,"phoneExt":13,"email":66},"Orli Hellerstein","604 822 0332","orli.hellerstein@ubc.ca",{"name":68,"role":22,"phone":13,"phoneExt":13,"email":13},"Raymond W Lam, MD",{"facility":70,"status":33,"city":71,"state":72,"zip":73,"country":37,"countryCode":38,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Nova Scotia Health Authority","Halifax","Nova Scotia","B3H 2E2",{"type":40,"coordinates":75},[76,77],-63.57688,44.64269,{"lat":77,"lon":76},[80,84],{"name":81,"role":26,"phone":82,"phoneExt":13,"email":83},"Mayank Ramchandani","902-473-1782","Mayank.Ramchandani@nshealth.ca",{"name":85,"role":22,"phone":13,"phoneExt":13,"email":13},"Rudolf Uher, MD",{"facility":87,"status":33,"city":88,"state":89,"zip":90,"country":37,"countryCode":38,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"McMaster University","Hamilton","Ontario","L8P 3B6",{"type":40,"coordinates":92},[93,94],-79.84963,43.25011,{"lat":94,"lon":93},[97,100],{"name":98,"role":26,"phone":99,"phoneExt":28,"email":29},"Saba Khoshroo, MSc","905 522 1155",{"name":101,"role":22,"phone":13,"phoneExt":13,"email":13},"Benicio N Frey, MD, PhD",{"facility":103,"status":33,"city":104,"state":89,"zip":105,"country":37,"countryCode":38,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Queen's University","Kingston","K7L4X3",{"type":40,"coordinates":107},[108,109],-76.48098,44.22976,{"lat":109,"lon":108},[112,117],{"name":113,"role":26,"phone":114,"phoneExt":115,"email":116},"Rida Khan","613-544-4900","53354","khanr@providencecare.ca",{"name":118,"role":22,"phone":13,"phoneExt":13,"email":13},"Roumen Milev, MD, PhD",{"facility":120,"status":33,"city":121,"state":89,"zip":122,"country":37,"countryCode":38,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"University of Ottawa","Ottawa","K1Z 7K4",{"type":40,"coordinates":124},[125,126],-75.69812,45.41117,{"lat":126,"lon":125},[129,134],{"name":130,"role":26,"phone":131,"phoneExt":132,"email":133},"Yamini Singh","613.722.6521","6405","yamini.singh@theroyal.ca",{"name":135,"role":22,"phone":13,"phoneExt":13,"email":13},"Pierre Blier, MD, PhD",{"facility":137,"status":33,"city":138,"state":89,"zip":139,"country":37,"countryCode":38,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"University Health Network","Toronto","M5T 2S8",{"type":40,"coordinates":141},[142,143],-79.39864,43.70643,{"lat":143,"lon":142},[146,151],{"name":147,"role":26,"phone":148,"phoneExt":149,"email":150},"Marianne Bautista","(416) 603-5800","6311","Marianne.Bautista@uhn.ca",{"name":152,"role":22,"phone":13,"phoneExt":13,"email":13},"Joshua Rosenblat, MD",{"facility":154,"status":33,"city":138,"state":89,"zip":155,"country":37,"countryCode":38,"cosmosGeoPoint":156,"geoPoint":158,"contacts":159},"Centre for Addiction and Mental Health","M6J 1H4",{"type":40,"coordinates":157},[142,143],{"lat":143,"lon":142},[160,163],{"name":161,"role":26,"phone":13,"phoneExt":13,"email":162},"Aidan Schottler-Raymond","Aidan.Schottler-Raymond@camh.ca",{"name":164,"role":22,"phone":13,"phoneExt":13,"email":13},"Lena Quilty, PhD",{"facility":166,"status":33,"city":167,"state":89,"zip":168,"country":37,"countryCode":38,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Ontario Shores Centre for Mental Health Sciences","Whitby","L1N 5S9",{"type":40,"coordinates":170},[171,172],-78.93287,43.88342,{"lat":172,"lon":171},[175,180],{"name":176,"role":26,"phone":177,"phoneExt":178,"email":179},"Houra Parsinejad","905.430.4055","6134","parsinejadh@ontarioshores.ca",{"name":181,"role":22,"phone":13,"phoneExt":13,"email":13},"Daniel Mueller, MD, PhD",{"type":22,"investigatorFullName":183,"investigatorTitle":184,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"Benicio Frey","Professor, Department of Psychiatry and Behavioural Neurosciences",[186,188,189,190,191,192,193,195,196,198,200],{"name":187,"class":6},"Unity Health Toronto",{"name":154,"class":6},{"name":103,"class":6},{"name":120,"class":6},{"name":53,"class":6},{"name":32,"class":6},{"name":194,"class":6},"McGill University",{"name":70,"class":6},{"name":197,"class":6},"University of Michigan",{"name":199,"class":6},"Simon Fraser University",{"name":201,"class":6},"University Health Network, Toronto","100054287","an-innovative-master-platform-for-clinical-trials-in-mood-disorders-100054287",false,"NCT06408012","An Innovative Master Platform for Clinical Trials in Mood Disorders","Enabling Neuroscience Research Approaches for Brain, feeLings and Emotions (ENABLE): An Innovative Platform for Clinical Trials in Mood Disorders","ENABLE","Inclusion Criteria\n\nPatients:\n\n1. 16 years of age or older.\n2. Meet criteria for bipolar or depressive disorders as defined by DSM-5.\n3. Fluency in English, sufficient to complete the interviews and self-report questionnaires.\n\nInclusion Criteria\n\nHealthy Comparison (HC) Participants:\n\n1. 16 years of age or older.\n2. No history of psychiatric disorders (according to DSM-5) or significant unstable medical conditions.\n3. Fluency in English, sufficient to complete the interviews and self-report questionnaires.",true,"ALL","16 Years",{"count":214,"type":215},2200,"ESTIMATED","1 Day","OBSERVATIONAL","Mood disorders such as depression and bipolar disorder affect over 350 million people around the world. While several effective treatments exist, it is often difficult to match the right treatment to an individual person. Repeated efforts to find the right treatment contribute to poor functioning, low quality of life, and prolongs the time it takes to get well. Most areas of medicine are able to use 'biomarkers' or clinical tests, blood tests, or imaging to help diagnose and treat illness. The search for biomarkers in mood disorders is advancing, but one roadblock to progress is the lack of large, standardized studies of mood disorders that are needed to accurately identify biomarkers. The aim of the ENABLE platform is to provide the Canadian neuroscience community a standardized way of collecting biomarker data from individuals with a range of mood disorders symptoms. In addition, this 'master clinical trial platform' framework will provide a pool of participants who can be recruited into biomarker-based clinical trials.",[220,221,222],"Mood Disorders","Depressive Disorder","Bipolar and Related Disorders","2026-07-10",{"date":225,"type":226},"2026-07-13","ACTUAL",{"date":228,"type":226},"2023-10-17",{"date":230,"type":215},"2029-03-31",{"name":5,"class":6},9]